Black Diamond Therapeutics, Inc. (BDTX) stock

BDTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30

$1.52−0.09 (-5.59%)

Close on Nov 12, 2026Market cap $87.33MP/E –Yield –

Black Diamond Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

Black Diamond Therapeutics's operating margin for the twelve months ending Dec 31, 2025 was 17.9%. For fiscal 2025 it was 17.9%.

Period	Period end	Value	Change (pts)
FY2025	Dec 31, 2025	17.9%	–

Change is against the same quarter a year earlier.

Period	Period end	Value	Change (pts)
Q1 FY2025	Mar 31, 2025	77.9%	–

Parsed from the XBRL in Black Diamond Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BDTX.

Revenue growth-100.0% · median 7.2%

Advertisement
300 × 250

See a number that looks wrong?